Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6472MR)

This product GTTS-WQ6472MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6472MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14085MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ13602MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ1192MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ13559MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ1322MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ1626MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ796MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ776MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AB0024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW